G1 Therapeutics to Participate in the 22nd Annual Needham Virtual Healthcare Conference
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, will participate in the 22nd Annual Needham Virtual Healthcare Conference on April 18, 2023, at 1:30 PM EDT.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, will participate in the 22nd Annual Needham Virtual Healthcare Conference on April 18, 2023, at 1:30 PM EDT. CEO Jack Bailey and other executives will engage in a fireside chat during the event, which will be held virtually. Interested parties can access the webcast through the Events & Presentations page on G1 Therapeutics' website. The company focuses on developing next-generation therapies for cancer treatment, including its first product, COSELA® (trilaciclib). G1 Therapeutics is based in Research Triangle Park, North Carolina, and is committed to improving the lives of cancer patients through innovative therapies.
Details
News Market Reaction – GTHX
The recorded move for GTHX in the trading session of this news was +2.80%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
RESEARCH TRIANGLE PARK, N.C., April 11, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that G1’s Chief Executive Officer Jack Bailey and other members of the Executive Team will participate in a fireside chat during the 22nd Annual Needham Virtual Healthcare Conference. The fireside chat will take place on Tuesday April 18th at 1:30 PM EDT.
This meeting is being held virtually; the webcast of the event will be accessible on the Events & Presentations page of http://www.g1therapeutics.com.
About G1 Therapeutics
G1 Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of next generation therapies that improve the lives of those affected by cancer, including the Company’s first commercial product, COSELA® (trilaciclib). G1 has a deep clinical pipeline and is executing a development plan evaluating trilaciclib in a variety of solid tumors, including breast, lung, and bladder cancers. G1 Therapeutics is based in Research Triangle Park, N.C. For additional information, please visit www.g1therapeutics.com and follow us on Twitter @G1Therapeutics.
G1 Therapeutics® and the G1 Therapeutics logo and COSELA® and the COSELA logo are trademarks of G1 Therapeutics, Inc
Contacts:
Will Roberts
Vice President, Investor Relations & Corporate Communications
919-907-1944
wroberts@g1therapeutics.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.